Phase 1 Myasthenia Gravis Trial, Recruiting NCT07215650 Sponsor: Candid Therapeutics Condition: Myasthenia Gravis
Back to Myasthenia Gravis

Phase 1 Myasthenia Gravis Trial, Recruiting

NCT07215650
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older at the time of signing the consent form
  • You have been diagnosed with Myasthenia Gravis (MG) at a moderate to moderately severe level, and your doctor does not expect you to need breathing support during the study
  • Your MG symptoms significantly affect daily life, measured by specific scoring tools, with more than just eye-related symptoms (confirm with trial site for exact score thresholds)
  • Your MG has not responded well enough to standard treatments such as steroids, immune-suppressing medications, or certain biological drugs, or there are no effective treatment options available for you

Who may not be able to join:

  • You have previously received a type of advanced immune cell therapy called CAR-T, a T-cell engaging therapy, or a treatment targeting a protein called BCMA
  • You have taken certain immune-suppressing medications not listed in the trial protocol within roughly the past 3 months (unless the medical team approves an exception)
  • You have taken part in another clinical trial using a non-biological experimental treatment within about 4 weeks before joining this study
  • You have taken part in another clinical trial using a biological experimental treatment within about 3 months before joining this study
  • You received a live vaccine within 4 weeks before the screening visit
  • You have a history of a serious brain condition called progressive multifocal leukoencephalopathy
  • You have a history of a primary immune system deficiency or an inherited condition affecting part of your immune system called the complement system
  • You have one or more serious ongoing health conditions, such as poorly controlled diabetes, advanced kidney disease, severe lung disease requiring oxygen, or respiratory failure
  • You have any other serious medical condition or significant abnormal lab results that your doctor believes would make participation unsafe or affect the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8618521520014

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Candid Therapeutics
Registry
ClinicalTrials.gov
Start date
16 September 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of treatment-emergent adverse events through end of study; Changes from baseline in vital signs through end of study: body temperature; Changes from baseline in vital signs through end of study: heart rate; Changes from baseline in vital signs through end of study: respiratory rate; Changes from baseline in vital signs through end of study: blood pressure; Changes from baseline in vital signs through end of study: pulse oximetry; Changes from baseline in ECG parameters through end of study: PR interval; Changes from baseline in ECG parameters through end of study: QRS in...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov